TORONTO, November 10, 2025 — Leads & Copy — MediPharm Labs Corp. (TSX: LABS) will release its third-quarter financial results for the three and nine months ended September 30th, 2025, before markets open on Thursday, November 13th, 2025.
MediPharm Labs’ executive management team will host a conference call and webcast on Thursday, November 13th, 2025, at 10:00 a.m. (Eastern time) to discuss the company’s financial results.
To access the conference call, dial (888) 330-2454 (North America Toll-Free) or +1 (240) 789-2714 (International Toll) and use Conference ID: 4921762. Participants should dial in approximately 15 minutes before the start of the call.
A live webcast will be available here. A replay will be available approximately one day after completion of the call at https://www.medipharmlabs.com/investors for those unable to participate live.
MediPharm Labs, founded in 2015, specializes in developing and manufacturing purified, pharmaceutical-quality cannabis concentrates, active pharmaceutical ingredients (API), and advanced derivative products. The company operates a Good Manufacturing Practices (GMP) certified facility with ISO standard-built clean rooms.
MediPharm Labs has invested in a research-driven team, state-of-the-art technology, downstream purification methodologies, and purpose-built facilities to deliver pure, trusted, and precision-dosed cannabis products.
In 2021, MediPharm Labs received a Pharmaceutical Drug Establishment License from Health Canada, becoming the only company in North America to hold a commercial-scale domestic GMP License for the extraction of multiple natural cannabinoids. This GMP license is the first step in the company’s current foreign drug manufacturing site registration with the US FDA.
In 2023, MediPharm acquired VIVO Cannabis Inc., expanding MediPharm’s reach to medical patients in Canada via Canna Farms medical e-commerce platform, and in Australia and Germany through Beacon Medical PTY and Beacon Medical GMBH. This acquisition also included Harvest Medical Clinics in Canada, providing medical cannabis patients with physician consultations for medical cannabis education and prescriptions.
The company operates in compliance with all applicable laws in the countries in which it operates.
MediPharm Labs Investor Relations, 1 416.913.7425, investors@medipharmlabs.com
Source: MediPharm Labs Corp.
